You are hereDecember 4, 2020
LXR Agonist-treated EOCs Decrease Atherosclerosis
Patient‐derived early outgrowth cells (EOCs), an endothelial progenitor cell-derived cell population, are currently under investigation as a potential treatment for vascular diseases such as pulmonary hypertension and myocardial infarction. The findings of a new STEM CELLS Translational Medicine study from the lab of Carolyn L. Cummins (University of Toronto, Ontario, Canada) demonstrate that liver X receptor (LXR) activation in mouse EOCs causes the secretion of factors that reduce binding of inflammatory cells to endothelial cells and decrease the development of atherosclerosis. Rasheed et al. also report that LXR agonist-treated EOCs derived from human coronary artery disease patients recapitulate these results. Overall, this study suggests that administration of autologous LXR agonist-treated EOCs and/or the cell secretome may help inhibit atherosclerotic progression.